CN110339134B - 一种防治脱发组合物、防治脱发产品及其制备方法 - Google Patents
一种防治脱发组合物、防治脱发产品及其制备方法 Download PDFInfo
- Publication number
- CN110339134B CN110339134B CN201910778312.8A CN201910778312A CN110339134B CN 110339134 B CN110339134 B CN 110339134B CN 201910778312 A CN201910778312 A CN 201910778312A CN 110339134 B CN110339134 B CN 110339134B
- Authority
- CN
- China
- Prior art keywords
- preventing
- pollen
- alopecia
- composition
- treating alopecia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 128
- 231100000360 alopecia Toxicity 0.000 title claims abstract description 115
- 230000003405 preventing effect Effects 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 235000000719 Prunus africana Nutrition 0.000 claims abstract description 45
- 241000200478 Prunus africana Species 0.000 claims abstract description 45
- 239000002994 raw material Substances 0.000 claims abstract description 32
- 239000007788 liquid Substances 0.000 claims description 48
- 244000269722 Thea sinensis Species 0.000 claims description 37
- 235000013616 tea Nutrition 0.000 claims description 33
- 230000002265 prevention Effects 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 22
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 17
- 229940024606 amino acid Drugs 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 241000208340 Araliaceae Species 0.000 claims description 12
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 12
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 12
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 12
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 12
- 229940106189 ceramide Drugs 0.000 claims description 12
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 12
- 235000008434 ginseng Nutrition 0.000 claims description 12
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 12
- 229940109850 royal jelly Drugs 0.000 claims description 12
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 12
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 12
- 241001107116 Castanospermum australe Species 0.000 claims description 11
- 229930013930 alkaloid Natural products 0.000 claims description 11
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 11
- 235000021279 black bean Nutrition 0.000 claims description 11
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 11
- 235000013824 polyphenols Nutrition 0.000 claims description 11
- 229940089161 ginsenoside Drugs 0.000 claims description 10
- 229930182494 ginsenoside Natural products 0.000 claims description 10
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 9
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 9
- 235000008696 isoflavones Nutrition 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 238000000227 grinding Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 5
- IXVMHGVQKLDRKH-VRESXRICSA-N Brassinolide Natural products O=C1OC[C@@H]2[C@@H]3[C@@](C)([C@H]([C@@H]([C@@H](O)[C@H](O)[C@H](C(C)C)C)C)CC3)CC[C@@H]2[C@]2(C)[C@@H]1C[C@H](O)[C@H](O)C2 IXVMHGVQKLDRKH-VRESXRICSA-N 0.000 claims description 4
- IXVMHGVQKLDRKH-KNBKMWSGSA-N brassinolide Chemical compound C1OC(=O)[C@H]2C[C@H](O)[C@H](O)C[C@]2(C)[C@H]2CC[C@]3(C)[C@@H]([C@H](C)[C@@H](O)[C@H](O)[C@@H](C)C(C)C)CC[C@H]3[C@@H]21 IXVMHGVQKLDRKH-KNBKMWSGSA-N 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 30
- 210000004209 hair Anatomy 0.000 abstract description 18
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract description 17
- 208000001840 Dandruff Diseases 0.000 abstract description 14
- 230000003676 hair loss Effects 0.000 abstract description 13
- 208000024963 hair loss Diseases 0.000 abstract description 13
- 230000003779 hair growth Effects 0.000 abstract description 11
- 230000028327 secretion Effects 0.000 abstract description 9
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 230000001076 estrogenic effect Effects 0.000 abstract description 5
- 229940088597 hormone Drugs 0.000 abstract description 5
- 239000005556 hormone Substances 0.000 abstract description 5
- 230000000638 stimulation Effects 0.000 abstract description 2
- 230000003450 growing effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 34
- 230000000052 comparative effect Effects 0.000 description 33
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 22
- 230000003658 preventing hair loss Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 210000004761 scalp Anatomy 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 13
- 229960003604 testosterone Drugs 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 9
- 210000003780 hair follicle Anatomy 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000003098 androgen Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010009736 Protein Hydrolysates Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 239000003531 protein hydrolysate Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- 229940107131 ginseng root Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 235000014705 isoleucine Nutrition 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000008729 phenylalanine Nutrition 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 235000013930 proline Nutrition 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- 238000001132 ultrasonic dispersion Methods 0.000 description 2
- 235000014393 valine Nutrition 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- AWFYPPSBLUWMFQ-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=C2 AWFYPPSBLUWMFQ-UHFFFAOYSA-N 0.000 description 1
- 241000606434 Babylonia Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N Epristeride Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229950009537 epristeride Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical group O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- JBJWASZNUJCEKT-UHFFFAOYSA-M sodium;hydroxide;hydrate Chemical compound O.[OH-].[Na+] JBJWASZNUJCEKT-UHFFFAOYSA-M 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于生发技术领域,尤其涉及一种防治脱发组合物、防治脱发产品及其制备方法。本发明提供了一种组合物,所述组合物的原料包括:油菜花粉、裸麦花粉和非洲臀果木。本发明中,油菜花粉具有雌激素样作用,减少头屑、防脱/生发,裸麦花粉和非洲臀果木能够有效地抑制5α‑还原酶活性,减少雄性激素的过度分泌。实验结果表明,本发明提供的上述特定组分和配比的防治脱发组合物能够协同作用达到防治脱发的效果,本发明防治脱发组合物的防脱/生发效果显著,对皮肤无刺激作用。
Description
技术领域
本发明属于生发技术领域,尤其涉及一种防治脱发组合物、防治脱发产品及其制备方法。
背景技术
近年来,随着社会经济发展,生活节奏加快,工作和心理压力增加,睡眠不足、内分泌失调及高油脂食物的过量摄取等因素的影响,使得脱发人群数量加速增加,并呈现年轻化趋势。脱发在临床上的原因包括雄激素过度分泌、神经性、真菌感染、内分泌失调、皮脂过量溢出、营养性、微循环不畅及先天性等,其中雄激素过度分泌及头皮血液循环不畅,不能将营养成分输送到头部表皮毛囊是引起脱发的重要因素之一,常伴有脂溢性皮炎、头屑增多等症状,多发生于皮脂腺分泌旺盛的青壮年。
长期以来脱发困扰人们的正常生活,因此对于生发、护发和养发的产品研发备受人们的关注。目前防治脱发的药物和生发液已有很多,但是,存在着治愈率低的问题。
发明内容
有鉴于此,本发明提供了一种防治脱发组合物、防治脱发产品及其制备方法,用于解决现有防治脱发的药物和生发液存在着治愈率低的问题。
本发明的具体技术方案如下:
一种防治脱发组合物,所述防治脱发组合物的原料包括:油菜花粉、裸麦花粉和非洲臀果木。
优选的,所述油菜花粉、所述裸麦花粉和所述非洲臀果木的质量比为1~5:1~5:1~5。
优选的,所述油菜花粉、所述裸麦花粉和所述非洲臀果木的质量比为1:1:1。
优选的,所述油菜花粉中油菜素内酯的含量为0.01%~1%。
优选的,所述原料还包括人参、黑豆、茶叶和蜂王浆水解蛋白中的一种或多种。
优选的,所述原料还包括透明质酸钠、神经酰胺和氨基酸中的一种或多种。
本发明还提供了一种防治脱发产品,包括:上述技术方案所述防治脱发组合物和日化领域可接受的辅助成分。
优选的,所述人参中的人参皂苷含量为0.01%~5%;
所述黑豆中的异黄酮含量为0.1%~10%;
所述茶叶中的生物碱含量为0.5%~4%,所述茶叶中的茶多酚含量为10%~35%。
优选的,所述防治脱发产品为防治脱发液;
所述防治脱发液的溶剂为乙醇水溶液。
本发明还提供了一种防治脱发产品的制备方法,包括以下步骤:
将油菜花粉、裸麦花粉和非洲臀果木研磨成粒径为100μm~200μm的粉末,再将所述粉末采用乙醇水溶液进行提取,得到防治脱发产品。
综上所述,本发明提供了一种防治脱发组合物,所述防治脱发组合物的原料包括:油菜花粉、裸麦花粉和非洲臀果木。本发明中,油菜花粉具有雌激素样作用,减少头屑、防脱/生发,裸麦花粉和非洲臀果木能够有效地抑制5α-还原酶活性,减少雄性激素的过度分泌。实验结果表明,本发明提供的上述特定组分和配比的防治脱发组合物能够协同作用达到防治脱发的效果,本发明防治脱发组合物的治愈率高,对皮肤无刺激作用。
具体实施方式
本发明提供了一种防治脱发组合物、防治脱发产品及其制备方法,用于解决现有防治脱发的药物和生发液存在着治愈率低和疗程长的问题。
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
一种防治脱发组合物,防治脱发组合物的原料包括:油菜花粉、裸麦花粉和非洲臀果木。
本发明中,油菜花粉具有雌激素样作用,减少头屑、防脱/生发,裸麦花粉和非洲臀果木能够抑制5α-还原酶,抑制雄性激素的过度分泌。实验结果表明,本发明提供的上述特定组分和配比的防治脱发组合物能够协同作用达到防治脱发的效果,本发明防治脱发组合物的治愈率高,对皮肤无刺激作用。
本发明中,油菜花粉、裸麦花粉和非洲臀果木的质量比为1~5:1~5:1~5。
进一步的,油菜花粉、裸麦花粉和非洲臀果木的质量比为1:1:1。
本发明中,非洲臀果木具体为非洲臀果木皮。
本发明中,油菜花粉中油菜素内酯的含量为0.01%~1%。
进一步的,原料还包括人参、黑豆、茶叶和蜂王浆水解蛋白中的一种或多种。
进一步的,原料还包括透明质酸钠、神经酰胺和氨基酸中的一种或多种。
现有技术中,非那雄胺(Finasteride)等虽然具有刺激头皮达到生发效果,但不能改善头皮、毛囊和发根的生态环境。酮康哩洗剂等抑制头皮表面的真菌,也仅是对脱发起到一定的辅助治疗作用。
本发明中,人参中的人参皂苷能够促进血液循环,改善毛囊环境;黑豆中的异黄酮具有雌激素样作用,减少头屑、防脱/生发;茶叶中的生物碱能够抑制5α-还原酶,抑制雄性激素的过度分泌,茶叶中的茶多酚能够抗菌消炎,抑制头屑生长;蜂王浆水解蛋白具有雌激素样作用,防脱/生发;透明质酸钠具有保湿作用,能够抑制头屑,激活毛囊活力;神经酰胺能够滋养发根,抑制头屑,激活毛囊活力;氨基酸能够滋养头皮,坚固发根,激活毛囊,重塑生发微环境。
本发明防治脱发组合物通过抑制雄性激素过度分泌、防治脱发并促进生长、杀菌抑菌和抗炎、促进头皮血液微循环、改善毛囊环境及滋养发根等作用共同完成防脱/生发效果。并且,本发明防治脱发组合物原料天然,具有无刺激性、无依赖性及无毒副作用,能够防治脱发,改善头皮营养,促进生发,还能够抑制头屑生成,生发效果好,使用方便,可有效地用于雄性激素性脱发、产后脱发或遗传性脱发等人群,对溢脂性脱发和头屑生成具有显著的疗效。
本发明中,以质量份计,优选为油菜花粉、裸麦花粉和非洲臀果木3~15份,人参1~5份,黑豆1~5份,茶叶1~5份,蜂王浆水解蛋白0.1~1.5份,透明质酸钠0.01~0.05份,神经酰胺0.1~1.5份,氨基酸1~5份;更优选为油菜花粉、裸麦花粉和非洲臀果木3~15份,人参2~3份,黑豆1~3份,茶叶2~3份,蜂王浆水解蛋白0.5~1.0份,透明质酸钠0.02~0.03份,神经酰胺0.5~1.0份,氨基酸2~3份;进一步优选为油菜花粉、裸麦花粉和非洲臀果木3份,人参2份,黑豆1份,茶叶2份,蜂王浆水解蛋白0.25份,透明质酸钠0.025份,神经酰胺0.5份,氨基酸1份。
本发明还提供了一种防治脱发产品,包括上述技术方案防治脱发组合物和日化领域可接受的辅助成分。
本发明中,人参中的人参皂苷含量为0.01%~5%;
黑豆中的异黄酮含量为0.1%~10%;
茶叶中的生物碱含量为0.5%~4%,茶叶中的茶多酚含量为10%~35%。
氨基酸包括精氨酸、天冬氨酸、甘氨酸、丙氨酸、丝氨酸、缬氨酸、脯氨酸、苏氨酸、异亮氨酸、组氨酸和苯丙氨酸中的一种或多种。
本发明中,防治脱发产品为防治脱发液;
防治脱发液的溶剂为乙醇水溶液。
本发明中,采用液体剂型,使用更加便利。需要说明的是,防治脱发产品还可为膏剂、粉剂等其它剂型。
溶剂的质量分数优选为防治脱发液的90%~99.9%,更优选为98%~99.5%,溶剂还可起着清凉头皮的作用。溶剂中,乙醇水溶液中乙醇的体积分数为40%~65%,优选为45%~55%,更优选为50%。
本发明中,防治脱发产品中还包括香精,作为芳香剂,起着调香作用。香精的质量分数优选为防治脱发液的0.01%~1.5%,更优选为0.01%~0.05%。
本发明防治脱发液的使用方法为:取适量本发明防治脱发液均匀喷洒或涂抹于头皮及发根处,轻柔按摩头皮至吸收,每日二次,早晚使用,一个月为一个疗程。临床实验表明使用三个疗程后效果显著。
本发明还提供了一种防治脱发产品的制备方法,包括以下步骤:
将油菜花粉、裸麦花粉和非洲臀果木研磨成粒径为100μm~200μm的粉末,再将粉末采用乙醇水溶液进行提取,得到防治脱发产品。
现有技术中,含有中药及植物成分的生发液有效成分由于颗粒大,不能有效地被头部皮肤吸收,从而影响使用效果。
本发明防治脱发产品的制备方法中,将油菜花粉、裸麦花粉和非洲臀果木研磨成粒径为100μm~200μm的粉末,优选为150μm,即100目的粉末,再将粉末采用乙醇水溶液进行提取,以乙醇作为提取介质,得到防治脱发产品,防治脱发产品的有效成分易于被头部皮肤吸收。
本发明防治脱发产品的制备方法中,乙醇水溶液中乙醇的体积分数为40%~65%,优选为50%;粉末与乙醇水溶液的质量比为0.01~5:95~99.9,优选为0.01:99.9。
本发明防治脱发产品优选为防治脱发液,便于携带,使用方便。
本发明制备方法中,粉末的原料还包括人参、黑豆和茶叶,粉末的原料优选还包括人参皂苷、异黄酮、茶叶生物碱和茶多酚。
茶叶生物碱可通过酸提碱沉的方法进行富集,制备方法包括:将茶叶放入研磨机中研磨成100目细粉,称取重量后,添加10倍盐酸-水溶液(pH 2~4)浸泡过夜,加热回流提取2h,重复提取三次,合并提取液,用碳酸氢钠调pH至碱性(pH 8~9),然后用等体积氯仿进行萃取三次,合并萃取液并减压浓缩,得到茶叶生物碱。
茶多酚成分可通过碱提酸沉的方法进行富集,制备方法包括:将茶叶放入研磨机中研磨成100目细粉,称取重量后,添加10倍量氢氧化钠-水溶液(pH8~9)浸泡过夜,加热回流提取2h,重复提取三次,合并提取液,用盐酸调pH至酸性(pH 3~4),然后用等体积氯仿进行萃取三次,合并萃取液并减压浓缩,得到茶多酚。
本发明制备方法中,优选将粉末在100℃下采用乙醇水溶液进行1h提取,优选将提取得到的浓缩液减压浓缩,干燥,优选加入人参皂苷、异黄酮、茶叶生物碱和茶多酚混合,放入研磨机中研磨成100目细粉,加入乙醇水溶液与蜂王浆水解蛋白、透明质酸钠、神经酰胺和氨基酸,在40kHZ频率下超声分散30min,将超声分散后的液体进行灭菌包装,得到防治脱发液。
为了进一步理解本发明,下面结合具体实施例对本发明进行详细阐述。
具体实施例中,非洲臀果木具体为非洲臀果木皮,油菜花粉购自枞阳鲍记蜂业,裸麦花粉、非洲臀果木皮和苦参根购自湖北远诚科技,人参皂苷购自中国药品生物制品所,蜂王浆水解蛋白、透明质酸钠、神经酰胺和氨基酸购自日本广州千羽化工。
实施例1
本实施例进行防治脱发液的制备,包括以下步骤:
将油菜花粉、裸麦花粉和非洲臀果木研磨成粒径为100目的粉末,再将粉末采用体积分数为50%的乙醇水溶液在100℃下进行1h提取,将提取得到的浓缩液减压浓缩,干燥,再放入研磨机中研磨成100目细粉,加入乙醇水溶液,在40kHZ频率下超声分散30min,得到防治脱发液。防治脱发液中,乙醇水溶液的质量分数为99.9%,乙醇在乙醇水溶液的体积分数为50%。其中,油菜花粉、裸麦花粉和非洲臀果木的质量比为1:1:1。
实施例2
本实施例进行防治脱发液的制备,与实施例1相同,油菜花粉、裸麦花粉和非洲臀果木即总原料的质量与实施例1相同,但油菜花粉、裸麦花粉和非洲臀果木的质量比为1:1:5。
实施例3
本实施例进行防治脱发液的制备,与实施例1相同,总原料的质量与实施例1相同,但油菜花粉、裸麦花粉和非洲臀果木的质量比为1:1:8。
实施例4
本实施例进行防治脱发液的制备,包括以下步骤:
将油菜花粉、裸麦花粉和非洲臀果木研磨成粒径为100目的粉末,再将粉末采用体积分数为50%的乙醇水溶液在100℃下进行1h提取,将提取得到的浓缩液减压浓缩,干燥,加入人参皂苷、异黄酮、茶叶生物碱和茶多酚混合,再放入研磨机中研磨成100目细粉,加入乙醇水溶液与蜂王浆水解蛋白、透明质酸钠、神经酰胺和氨基酸,在40kHZ频率下超声分散30min,得到防治脱发液。防治脱发液中,乙醇水溶液的质量分数为99.9%,乙醇在乙醇水溶液的体积分数为50%。其中,油菜花粉、裸麦花粉和非洲臀果木的质量比为1:1:1,油菜花粉、人参皂苷、异黄酮、茶叶生物碱、茶多酚、蜂王浆水解蛋白、透明质酸钠、神经酰胺和氨基酸的质量比为1:1:1:1:2:1:0.1:0.02:0.1,氨基酸包括甘氨酸、丙氨酸、缬氨酸、异亮氨酸、苯丙氨酸、天冬氨酸、丝氨酸、苏氨酸、脯氨酸、组氨酸和精氨酸,每种氨基酸的质量相同。
本实施例总原料(油菜花粉、裸麦花粉、非洲臀果木、人参皂苷、异黄酮、茶叶生物碱、茶多酚、蜂王浆水解蛋白、透明质酸钠、神经酰胺和氨基酸)的质量与实施例1相同。
对比例1
本对比例进行防治脱发液的制备,与实施例1相同,总原料的质量与实施例1相同,但原料中无油菜花粉。
对比例2
本对比例进行防治脱发液的制备,与实施例1相同,总原料的质量与实施例1相同,但原料中无裸麦花粉。
对比例3
本对比例进行防治脱发液的制备,与实施例1相同,总原料的质量与实施例1相同,但原料中无非洲臀果木。
对比例4
本对比例进行防治脱发液的制备,与实施例1相同,总原料的质量与实施例1相同,但原料中无油菜花粉和裸麦花粉。
对比例5
本对比例进行防治脱发液的制备,与实施例1相同,总原料的质量与实施例1相同,但原料中无油菜花粉和非洲臀果木。
对比例6
本对比例进行防治脱发液的制备,与实施例1相同,总原料的质量与实施例1相同,但原料中无裸麦花粉和非洲臀果木。
对比例7
本对比例进行防治脱发液的制备,与实施例1相同,总原料的质量与实施例1相同,但原料中油菜花粉替换为苦参根。
对比例8
本对比例进行防治脱发液的制备,与实施例1相同,总原料的质量与实施例1相同,但原料中裸麦花粉替换为苦参根。
实施例5皮肤刺激性测试
试验选用50名志愿者,年龄18~24岁,男女各半,均无皮肤疾患。根据中华人民共和国卫生部《化妆品卫生规范》2002版中对人体皮肤斑贴试验的基本原则和方法,进行本发明实施例1~4防治脱发液的人体皮肤班帖试验,具体方法为:将0.05ml防治脱发液作为受试样品滴加于斑试器所附滤纸片上,置于斑试器内。将斑试器贴于受试者背部,同时逐个轻压药室以驱除空气,并使试验物均匀分布,24h后移去受试样品,30min后观察结果,而后在24h重复观察,对照组为溶剂乙醇水溶液。试验结果请参阅表1,结果表明与对照组相比,本发明实施例1~4防治脱发液对皮肤无刺激作用。
表1实施例1~4防治脱发液的皮肤刺激性测试结果
受试物 | 无刺激/无红斑 | 轻度红斑 | 红斑 | 丘疹 | 严重丘疹 |
乙醇水溶液 | 10 | 0/10 | 0/10 | 0/10 | 0/10 |
实施例1防治脱发液(24h) | 10 | 0/10 | 0/10 | 0/10 | 0/10 |
实施例1防治脱发液(48h) | 10 | 0/10 | 0/10 | 0/10 | 0/10 |
实施例2防治脱发液(24h) | 10 | 0/10 | 0/10 | 0/10 | 0/10 |
实施例2防治脱发液(48h) | 10 | 0/10 | 0/10 | 0/10 | 0/10 |
实施例3防治脱发液(24h) | 10 | 0/10 | 0/10 | 0/10 | 0/10 |
实施例3防治脱发液(48h) | 10 | 0/10 | 0/10 | 0/10 | 0/10 |
实施例4防治脱发液(24h) | 10 | 0/10 | 0/10 | 0/10 | 0/10 |
实施例4防治脱发液(48h) | 10 | 0/10 | 0/10 | 0/10 | 0/10 |
实施例6 5α-还原酶抑制活性测试
5α-还原酶可使睾酮转变为生理活性更强的二氢睾酮,通过抑制5a-还原酶的活性,减少二氢睾酮的生成,是治疗雄激素依赖性疾病的有效手段,也是前列腺增生非手术治疗的主要途径。因此,通过测试5a-还原酶抑制活性,可以得知抑制雄性激素的能力。
前列腺组织的5α-还原酶活性测定:本研究通过RP-HPLC法直接检测底物睾酮浓度在酶促反应前后的变化,直观反应5α-还原酶的活性水平。
实验包括如下步骤:
将七周龄雄性清洁级SD大鼠乙醚麻醉后,在无菌条件下取出其前列腺并称重。然后将前列腺组织剪碎,加入5倍体积预冷的缓冲液(Tris 121.4mg,EDTA-2Na 1.8mg,MgCl·6H2O 102mg,2-巯基乙醇4.0mg,NaCl 0.292g,蔗糖4.5g),装入100ml容量瓶中,双蒸水定容至100ml,调整pH值到6.2,在冰浴中以20000r/min速度进行匀浆,并在4℃条件下10000r/min速度离心1h,小心去掉离心液上层的白色脂肪,收集上清,即得5α-还原酶提取物,以考马斯亮兰测定其蛋白含量为0.989mg/ml,分装后置于-80℃冰箱保存备用。
RP-HPLC色谱条件为:流动相为甲醇-水(80:20v/v),超声脱气1h,流速1.0ml/min,检测波长为242nm,柱温32℃,进样量为20μl。睾酮标准曲线的制备:准确称取睾酮标准对照品,用甲醇配制成1mg/ml的标准液,稀释成不同浓度,分别取不同浓度标准溶液进样,重复3次,测得峰面积,在0~100μg/ml浓度范围内,以峰面积均值与浓度作图,绘制标准曲线,回归方程y=1564x+6685,相关系数为R2=0.98。
实验分为14组,包括空白对照组、阳性对照组和实验组,反应体系为60μM的睾酮120μl、5α-还原酶提取物60μl、待测物60μl和120μM的NADPH120μl,空白对照组、阳性对照组和实验组的待测物体积相同,分别为水、艾普利特、实施例1~4防治脱发液或对比例1~8防治脱发液。各混合体系37℃反应15min,进样20μl,将样品中睾酮峰面积代入标准曲线计算相应浓度。实施例1~4防治脱发液或对比例1~8防治脱发液样品睾酮浓度减去5α-还原酶样品睾酮浓度即为底物反应后睾酮浓度,将无NADPH的样品睾酮浓度作为反应前底物睾酮浓度,求得反应前后底物睾酮浓度差ΔCT。根据酶活力单位定义,单位浓度酶液在37℃,pH=6.2条件下每分钟催化底物使其减少的量为一个酶活力单位,其计算公式为:5α-还原酶活力(U/L)=ΔCT/(15×0.989×60×10-3)。抑制率计算公式:I%=(ΔA。-ΔAn)/ΔA。×100%。其中,ΔA。为空白对照组的5α-还原酶活力,ΔAn为待测组的5α-还原酶活力。
统计学处理:实验数据以Student’s t test检验进行统计学处理,P<0.05有统计学意义。
结果请参阅表2,表2表明阳性药爱普列特对5α-还原酶具有良好的抑制作用,本发明实施例1~4防治脱发液对5α-还原酶的抑制作用明显优于对比例1~8防治脱发液,表明本发明采用特定组分(油菜花粉、裸麦花粉和非洲臀果木)和配比的组合物能够协同作用增强对5α-还原酶的抑制作用,并且实施例1防治脱发液对5α-还原酶的抑制作用优于实施例2和实施例3防治脱发液,表明油菜花粉、裸麦花粉和非洲臀果木的配比为1:1:1时,协同增强对5α-还原酶的抑制作用最佳。
表2实施例1~4和对比例1~8防治脱发液的5α-还原酶抑制活性测试结果
受试物 | 例数(n) | 抑制率% |
空白对照组 | 10 | 0 |
阳性对照组 | 10 | 80 |
实施例1 | 10 | 70 |
实施例2 | 10 | 66 |
实施例3 | 10 | 64 |
实施例4 | 10 | 72 |
对比例1 | 10 | 54 |
对比例2 | 10 | 55 |
对比例3 | 10 | 58 |
对比例4 | 10 | 50 |
对比例5 | 10 | 51 |
对比例6 | 10 | 52 |
对比例7 | 10 | 56 |
对比例8 | 10 | 57 |
实施例7防脱生发效果评价试验
本实验自2017年10月至2018年12月间接受使用人数140名,其中男性100例、女性40例,年龄30~55岁,重度脱发,88名,中度者42名,轻度者10名,将上述140人随机分为14组,包括空白对照组和实验组(实施例1~4和对比例1~8),每组10人,年龄及脱发状况等均无显著差异。试验方法为:实验组将实施例1~4和对比例1~8防治脱发液均匀涂抹于头皮及发根处,轻柔按摩头皮至吸收,一日早晚二次,一个月为一个疗程,共三个疗程,空白对照组涂抹乙醇水溶液,乙醇水溶液中乙醇的体积分数为50%,试验为双盲试验。
疗效判断标准为:(1)没有变化:头油、头屑和脱发状况没有改善,未见细发萌生,外观改善不明显;(2)轻微改善:痉痒感减少,头屑及脱发减轻,头皮环境部分改善,未见新发萌生。(3)显著改善:头屑及痉痒减轻,脱发减少,新发萌生,抑制皮脂过量分泌,外观有所改善,有效地改善头皮环境。
试验结果请参阅表3,结果表明与空白对照组相比,实施例1~4和对比例1~8防治脱发液均能够减轻脱发,具有轻微改善作用;本发明实施例1~4防治脱发液的效果明显优于对比例1~8防治脱发液,表明本发明采用特定组分(油菜花粉、裸麦花粉和非洲臀果木)和配比的组合物能够协同作用改善脱发,促进头发生长,并且实施例1防治脱发液的效果优于实施例2和实施例3防治脱发液,表明油菜花粉、裸麦花粉和非洲臀果木的配比为1:1:1时,协同增强作用最佳。与实施例1~3相比,实施例4的效果明显更优,表明采用实施例4原料制备的防治脱发液具有抗菌抗炎和止痒作用,能够有效抑制雄性激素的过度分泌,减少头皮皮脂,修复毛囊、滋养发根,增强头皮血液循环,能够使得头屑及脱发得到显著改善,出现明显的绒毛产生,促进头发再生。
表3实施例1~4和对比例1~8防治脱发液的防脱生发测试结果
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种防治脱发组合物,其特征在于,所述防治脱发组合物的原料包括:油菜花粉、裸麦花粉和非洲臀果木;
所述油菜花粉、所述裸麦花粉和所述非洲臀果木的质量比为1~5:1~5:1~5;
所述防治脱发组合物采用乙醇水溶液提取所述油菜花粉、所述裸麦花粉和所述非洲臀果木得到。
2.一种防治脱发组合物,其特征在于,所述防治脱发组合物的原料包括:油菜花粉、裸麦花粉和非洲臀果木;
所述油菜花粉、所述裸麦花粉和所述非洲臀果木的质量比为1:1:8;
所述防治脱发组合物采用乙醇水溶液提取所述油菜花粉、所述裸麦花粉和所述非洲臀果木得到。
3.根据权利要求1所述的防治脱发组合物,其特征在于,所述油菜花粉、所述裸麦花粉和所述非洲臀果木的质量比为1:1:1。
4.根据权利要求1所述的防治脱发组合物,其特征在于,所述油菜花粉中油菜素内酯的含量为0.01%~1%。
5.根据权利要求1~4任意一项所述的防治脱发组合物,其特征在于,所述原料还包括人参、黑豆、茶叶和蜂王浆水解蛋白中的一种或多种。
6.根据权利要求1~4任意一项所述的防治脱发组合物,其特征在于,所述原料还包括透明质酸钠、神经酰胺和氨基酸中的一种或多种。
7.一种防治脱发产品,其特征在于,包括:权利要求1至6任意一项所述防治脱发组合物和日化领域可接受的辅助成分。
8.根据权利要求7所述的防治脱发产品,其特征在于,所述防治脱发组合物包括人参、黑豆、茶叶和蜂王浆水解蛋白中的一种或多种;
所述人参中的人参皂苷含量为0.01%~5%;
所述黑豆中的异黄酮含量为0.1%~10%;
所述茶叶中的生物碱含量为0.5%~4%,所述茶叶中的茶多酚含量为10%~35%。
9.根据权利要求7所述的防治脱发产品,其特征在于,所述防治脱发产品为防治脱发液;
所述防治脱发液的溶剂为乙醇水溶液。
10.一种防治脱发产品的制备方法,其特征在于,包括以下步骤:
将油菜花粉、裸麦花粉和非洲臀果木研磨成粒径为100μm~200μm的粉末,再将所述粉末采用乙醇水溶液进行提取,得到防治脱发产品;
其中,所述油菜花粉、所述裸麦花粉和所述非洲臀果木的质量比为1~5:1~5:1~5,或所述油菜花粉、所述裸麦花粉和所述非洲臀果木的质量比为1:1:8。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910778312.8A CN110339134B (zh) | 2019-08-22 | 2019-08-22 | 一种防治脱发组合物、防治脱发产品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910778312.8A CN110339134B (zh) | 2019-08-22 | 2019-08-22 | 一种防治脱发组合物、防治脱发产品及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110339134A CN110339134A (zh) | 2019-10-18 |
CN110339134B true CN110339134B (zh) | 2020-10-16 |
Family
ID=68181037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910778312.8A Active CN110339134B (zh) | 2019-08-22 | 2019-08-22 | 一种防治脱发组合物、防治脱发产品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110339134B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111329795B (zh) * | 2020-04-02 | 2023-03-21 | 华熙生物科技股份有限公司 | 一种乌发育发组合物及其应用与乌发育发产品的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101128209A (zh) * | 2004-12-24 | 2008-02-20 | 都菲斯特股份有限公司 | 保健用制剂和治疗方法 |
EP2153836A1 (en) * | 2008-08-04 | 2010-02-17 | Polichem S.A. | Film-forming liquid formulations for drug release to hair and scalp |
CN108815088A (zh) * | 2018-09-18 | 2018-11-16 | 云南邦乐生物科技有限公司 | 一种防脱生发洗发液及其制备方法 |
-
2019
- 2019-08-22 CN CN201910778312.8A patent/CN110339134B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN110339134A (zh) | 2019-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110292552B (zh) | 一种具有抗敏修复功效的复方植物提取物及其制备方法和应用 | |
CN103585097B (zh) | 一种白及多糖载表皮生长因子复合物及其制备方法和应用 | |
KR100863890B1 (ko) | 차가버섯, 말굽잔나비버섯, 신령버섯 및 노루궁뎅이버섯혼합 추출물을 함유하는 화장료 조성물 | |
CN109223668B (zh) | 一种具有皮肤修复功效的二步发酵产物的制备方法和应用 | |
CN105147584A (zh) | 一种含中药成分的酵母发酵物及其制备方法和应用 | |
CN110613644A (zh) | 含大麻二酚纳米乳的护肤乳液及其制备方法 | |
KR102094846B1 (ko) | 피부 개선에 효능이 있는 혼합생약 화장료 조성물의 제조방법 및 이를 통해 제조된 혼합생약 화장료 조성물 | |
KR101207558B1 (ko) | 홍삼발효 초고압 추출물을 함유하는 화장료 조성물 | |
CN110339134B (zh) | 一种防治脱发组合物、防治脱发产品及其制备方法 | |
KR20040110441A (ko) | 초임계 유체 추출기법을 이용한 오기단(동충하초,가시오갈피, 영지버섯, 녹용 및 인삼)의 혼합추출물을함유한 화장료 조성물 및 그의 제조방법 | |
CN104027280A (zh) | 一种抗衰老中药组合物及其在化妆品中的应用 | |
KR20100031839A (ko) | 석류꽃 및 관동화 추출물을 함유하는 피부 외용제 조성물 | |
CN113101256A (zh) | 一种抗衰修复纳米乳及其应用 | |
KR102101949B1 (ko) | 우장지버섯 자실체 추출물 또는 우장지버섯 균사체 추출물을 함유하는 피부 외용제 또는 화장료 조성물 | |
CN112089666A (zh) | 一种抗氧化组合物及其制备方法和应用 | |
CN112136997A (zh) | 一种具有美白保湿功能的固体饮料及其制备方法 | |
CN107789282B (zh) | 一种含有铁皮石斛提取物和植物美白素的护肤品及其制备方法和应用 | |
KR101286266B1 (ko) | 화피 발효물을 유효성분으로 포함하는 탈모방지 또는 모발생장 촉진용 조성물 | |
CN114732847A (zh) | 一种控油防脱发组合物、控油防脱发产品及其制备方法 | |
KR20120053260A (ko) | 산뽕나무, 한련초, 지구자 추출물을 함유하는 피부 외용제 조성물 | |
CN115137675A (zh) | 一种具有保湿功效的复方植物提取物及应用 | |
CN110354050B (zh) | 一种延缓衰老组合物、制备方法及其应用 | |
CN101360478A (zh) | 含有红松提取物作为活性成分的化妆品组合物 | |
KR20070091482A (ko) | 피지분비 억제용 화장료 조성물 | |
CN113908087A (zh) | 一种天然保湿组合提取物,其制备方法以及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |